Maravai LifeSciences Holdings, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; unaudited. Maravai supplies products and services for nucleic acid production and biologics safety testing. Results include Alphazyme from its January 18, 2023 acquisition date.
Financial performance
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $79.0 million | $244.3 million | Down 67.7% |
| Gross profit / gross margin | $45.3 million / 57.4% | $204.3 million / 83.6% | Margin down 26.2 percentage points |
| Operating income / margin | $2.5 million / 3.2% | $167.4 million / 68.5% | Down 98.5% |
| Net income (loss) | $(1.3) million | $146.9 million | Compared with prior-year profit |
| Net income (loss) attributable to Maravai Holdings | $(0.1) million | $66.9 million | |
| Adjusted EBITDA, non-GAAP | $23.8 million | $187.0 million | |
| Operating cash flow | $85.1 million | $162.3 million | |
| Adjusted free cash flow, non-GAAP | $22.7 million | $184.2 million |
Nucleic Acid Production revenue was $61.5 million, down 72.5%; Biologics Safety Testing revenue was $17.6 million, down 14.9%. Segment adjusted EBITDA was $27.9 million and $13.7 million, respectively. These segment figures exclude corporate costs and other reconciling items and are not consolidated GAAP income.
Cash was $628.3 million at quarter-end. Long-term debt had $537.2 million of principal outstanding ($526.6 million carrying value); the $180 million revolving facility had no borrowings. The term loan rate was 7.63%, and the company reported compliance with debt covenants. Current assets were $765.5 million versus current liabilities of $124.9 million. Cash declined $3.9 million during the quarter.
Material changes and drivers
- Revenue contraction was driven primarily by lower CleanCap demand from COVID-19 vaccine customers. Management estimated COVID-19-related products and services at 20.1% of Q1 2023 revenue versus 70.8% a year earlier. CleanCap revenue was $28.9 million, of which an estimated $15.9 million was COVID-19-related, compared with $183.8 million and $172.9 million, respectively, in Q1 2022.
- Biologics Safety Testing revenue was affected by customer inventory normalization and China-related business headwinds, including slow return to work. The company also continued its decision not to ship into Russia.
- Gross margin fell with lower volume and an unfavorable product mix, higher personnel costs, increased excess and obsolete inventory reserves, and acquired-intangible amortization. SG&A increased 16.5%, including higher personnel and acquisition-related costs.
- Interest expense rose to $11.8 million from $2.7 million, reflecting higher rates and a change in the interest-rate-cap fair value. Interest income was $6.0 million. The income tax benefit was $3.2 million; the reported effective tax rate was 70.2% on a pretax loss.
- Operating cash flow was supported by working-capital movements, including an $82.4 million reduction in accounts receivable. Investing cash outflow was $69.7 million, including $69.7 million net cash paid for Alphazyme; financing cash outflow was $19.2 million, including tax distributions, debt repayment, and a MyChem acquisition holdback payment.
Outlook, risks and unusual items
- No specific revenue or earnings guidance is provided in the filing. Management expects COVID-19-related revenue to decline substantially from pandemic highs and says the longer-term level is highly uncertain, including due to customer-held inventory.
- Management expects 2023 capital expenditures of $57–$67 million, net of anticipated government funding, primarily for the Flanders San Diego facility. It believes cash, operating cash generation, and credit access will meet requirements over the next 12 months and beyond.
- The $719.6 million Tax Receivable Agreement (TRA) liability represents 85% of specified tax benefits payable to related parties. Assuming sufficient taxable income and no relevant tax-law changes, the company estimates payments of about $42.3–$63.3 million annually over the next 14 years, then declining. Actual timing and amounts may differ; a change of control, breach, or early termination could accelerate or increase cash obligations.
- Alphazyme consideration was $75.4 million, including $5.3 million of contingent consideration. Additional seller performance payments could reach $75 million, and employee retention payments total $9.3 million, subject to conditions. Acquisition purchase-price allocations remain preliminary. MyChem-related payments included a $9.7 million holdback payment in Q1.
- BARDA agreed to reimburse up to $38.8 million, or 50% of budgeted construction and validation costs, subject to agreement terms and possible recapture. In exchange, the company has conditional priority-access and preferred-pricing obligations during certain public health emergencies for 10 years after project completion.
- Risks highlighted include continued COVID-19 demand declines, customer and supplier concentration, macroeconomic and banking-system disruption, variable-rate debt, competition, and execution and integration of acquisitions. A significant portion of accessible domestic cash deposits exceeds FDIC insurance limits, though the company describes mitigation steps. No material litigation was identified; management reported effective disclosure controls.
Investor verification priorities
- Track revenue, CleanCap demand, COVID-19 exposure, customer inventory, and segment margins against the steep Q1 year-over-year decline.
- Reconcile operating cash flow and adjusted free cash flow to working-capital movements and the company’s non-GAAP definitions.
- Review liquidity after planned facility spending, debt interest and maturities, acquisition-related payments, tax distributions, and TRA obligations.
- Monitor Alphazyme revenue performance, contingent and retention payments, preliminary acquisition accounting, and integration benefits.
- Check the Flanders construction timeline, BARDA reimbursement conditions, and related long-term access and pricing commitments.